ユーザーIDをお忘れですか? or パスワードをお忘れですか?


Regulatory Affairs for Combination Products

Register for this On-demand Training Course training course to learn about FDA's approach to regulation of combination products, the processes to streamline development of single entity, and aligning requirements between drugs and devices.


Through a series of recorded sessions and interactive online exercises, this On-Demand Training Course will provide learners with an overview of FDA’s approach to regulation of combination products including review of FDA’s recent guidance. Topics will cover processes to streamline and integrate development of single entity, co-packaged and cross-labeled products. Discussion will cover approaches to aligning requirements between drugs and devices and assuring successful human factors interface. Course material will address FDA’s expectation for post-marketing activities, including safety reporting and manufacturing modifications.

This on-demand training course takes an average of 8 hours to complete. Learners have access to the course for one year from the date of purchase.


  • GMP compliance
  • Post-marketing safety
  • Post-approval changes
  • Streamlining device and drug systems
  • Specifications and design control
  • Risk assessment and management
  • Human factors interface


This program is designed for professionals involved in:

  • Regulatory affairs
  • Clinical affairs
  • Quality assurance
  • Manufacturing and CMC
  • Safety and pharmacovigilance
  • Project management


At the conclusion of this course, participants should be able to:

  • Compare the similarities and differences in drug and device regulations
  • Identify opportunities to streamline single entity compliance by integrating drug and device systems
  • Define risk assessment and management in the combination product environment
  • Identify the unique requirements of successful combination product development
  • Define FDA expectations of combination product applicants and how to work successfully with the agency
  • Determine how human factor considerations are assessed and controlled in the drug/device user interface